Stevanato Group price target lowered to $28 from $30 at BofA

BofA lowered the firm’s price target on Stevanato Group (STVN) to $28 from $30 and keeps a Buy rating on the shares. The firm notes Q4 results were ahead of Street estimates and while the FY26 guide reflects some near-term Engineering weakness due to recent order softness, underlying demand across biologics remains robust. Stevanato continues to benefit from a structural mix shift toward premium formats tied to broader biologics, supporting strong HVS growth even as GLPs moderate, BofA adds.